Simon Rule, MD, PhD
More than one-quarter of patients with relapsed/refractory mantle cell lymphoma (MCL) remained progression free and nearly half were alive at 3 years when treated with the BTK inhibitor ibrutinib (Imbruvica), according to results of a pooled analysis presented at the 2017 ASH Annual Meeting.1
- Rule S, Dreyling M, Goy A, et al. Median 3.5-year follow-up of ibrutinib treatment in patients with relapsed/refractory mantle cell lymphoma: a pooled analysis. In: Proceedings from the 2017 ASH Annual Meeting; December 9-12, 2017; Atlanta, Georgia. Abstract 151.
- Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507-516. doi: 10.1056/NEJMoa1306220.
... to read the full story